


## **MEDICINAL PRODUCTS 2018**




## Navidea Biopharmaceuticals Inc. Rank 1 of 49





## **MEDICINAL PRODUCTS 2018**





The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Navidea Biopharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 635% points. The greatest weakness of Navidea Biopharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 577%, being 599% points above the market average of -22%.

Input Variable	Value in 1000 USD
Assets, Current	13,832
Assets, Non-Current	1,445
General and Administrative Expense	11,170
Goodwill	458
Liabilities, Current	8,068
Liabilities, Non-Current	77
Other Assets	4,809
Other Compr. Net Income	-2.4
Other Expenses	-4,059
Other Liabilities	588
Other Net Income	84,760
Other Revenues	1,810
Property, Plant and Equipment, Net	237
Research and Development	4,514

Output Variable	Value in 1000 USD
Liabilities	8,733
Assets	20,781
Expenses	11,625
Revenues	1,810
Stockholders Equity	12,048
Net Income	74,946
Comprehensive Net Income	74,945
Economic Capital Ratio	577%

